

Connect Biopharma Holdings Limited

NOMINATING AND CORPORATE GOVERNANCE COMMITTEE CHARTER

I. Purpose

The purpose of the Nominating and Corporate Governance Committee (the “Committee”) of the Board of Directors (the “Board”) of Connect Biopharma Holdings Limited (the “Company”) is to identify individuals qualified to become Board members consistent with criteria approved by the Board, to oversee and make recommendations to the Board with respect to Board committee and leadership structure, to recommend that the Board select the director nominees for the next meeting of shareholders, to develop and recommend to the Board a set of Corporate Governance Guidelines, to oversee the evaluation of the Board, to oversee succession planning for the Chief Executive Officer, and to oversee aspects of the Company’s corporate governance functions and practices on behalf of the Board.

II. Composition

The Committee must consist of at least two directors, at least one of whom must satisfy the independence requirements of the Nasdaq Stock Market LLC (“Nasdaq”), subject to any available exception, and at least one of whom should be a member of Company management. Committee members must be appointed and may be removed, with or without cause, by the Board. Unless a Chair is designated by the Board, the Committee may designate a Chair by majority vote of the full Committee membership.

III. Meetings, Procedures and Authority

The Committee has the authority to establish its own rules and procedures for notice and conduct of its meetings so long as they are not inconsistent with any provisions of the Company’s Memorandum and Articles of Association that are applicable to the Committee.

The Committee has sole authority to retain and terminate any search firm to be used to identify director candidates, including sole authority to approve such search firm’s fees and other retention terms. The Committee has the authority to retain any other advisors that the Committee believes to be desirable and appropriate and has the authority to approve related fees and retention terms.

In addition to the duties and responsibilities expressly delegated to the Committee in this Charter, the Committee may exercise any other powers and carry out any other responsibilities consistent with this Charter, the purposes of the Committee, and the Company’s Memorandum and Articles of Association.

IV. Duties and Responsibilities

1. *Director Nominees.* The Committee will identify individuals qualified to become members of the Board and ensure that the Board has the requisite expertise and that its membership consists of persons with sufficiently diverse and independent backgrounds. The Committee will

also recommend to the Board the nominees for election to the Board at the next annual meeting of shareholders. The criteria to be used by the Committee in recommending directors and by the Board in nominating directors are as set forth in the Company's corporate governance guidelines.

2. *Board Committee Structure and Membership.* The Committee will annually review the Board committee structure and recommend to the Board for its approval directors to serve as members of each committee.

3. *Board Leadership Structure.* The Committee will periodically review the Board leadership structure to assess whether it is appropriate given the specific characteristics and circumstances of the Company and recommend any proposed changes to the Board.

4. *Corporate Governance Guidelines.* The Committee will develop and recommend to the Board the Corporate Governance Guidelines. The Committee will, from time to time as it deems appropriate, review and reassess the adequacy of such corporate governance guidelines and recommend any proposed changes to the Board for approval.

5. *Director Changes in Position or Circumstances.* The Committee will review any notification by a director of his or her resignation or material changes in employment or of circumstances that may adversely reflect upon the director or the Company, in accordance with the Corporate Governance Guidelines. Based on this review, the Committee may recommend that the Board request such director to resign from the Board.

6. *Board Evaluations.* The Committee will oversee any annual self-evaluations of the Board.

7. *Succession of Chief Executive Officer.* The Committee shall periodically oversee and review the continuity planning process for the Chief Executive Officer of the Company. Such planning process shall include contemplating transitional leadership in the event of an unplanned vacancy, as well as long-term succession planning, if feasible. With respect to any long-term succession planning deemed necessary or appropriate by the Committee, the Committee shall conduct a candidate identification and selection process and make recommendations to the Board regarding the selection of appropriate candidates to succeed the Chief Executive Officer.

8. *Other Corporate Governance Matters.* The Committee may make recommendations to the Board regarding governance matters, including, but not limited to, the Company's Memorandum and Articles of Association and the charters of the Company's other committees.

9. *Reports to the Board of Directors.* The Committee must report regularly to the Board regarding the activities of the Committee.

10. *Committee Self-Evaluation.* The Committee must at least annually perform an evaluation of the performance of the Committee.

11. *Review of this Charter.* The Committee must periodically review and reassess this Charter and submit any recommended changes to the Board for its consideration.

V. Delegation of Duties

In fulfilling its responsibilities, the Committee has the authority to delegate any or all of its responsibilities to a subcommittee of the Committee.

VI. Stockholders' Agreement

For so long as the Second Amended and Restated Shareholders Agreement, dated as of December 1, 2020, between the Company, its subsidiaries and certain of its shareholders is in effect, this Charter will be interpreted to be consistent with such agreement.

*Amended by the Board of Directors of Connect Biopharma Holdings Limited on
March 11, 2026*